1. Home
  2. MRNA

as of 12-03-2025 3:56pm EST

$25.14
+$1.08
+4.49%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Chart Type:
Time Range:
Founded: 2010 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 9.3B IPO Year: 2018
Target Price: $33.91 AVG Volume (30 days): 10.0M
Analyst Decision: Hold Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -8.05 EPS Growth: N/A
52 Week Low/High: $22.28 - $48.92 Next Earning Date: 11-06-2025
Revenue: $2,232,000,000 Revenue Growth: -56.07%
Revenue Growth (this year): -40.17% Revenue Growth (next year): 0.77%

AI-Powered MRNA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 81.65%
81.65%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: